Open for inclusion

A phase 1/2 multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenaöodomide (Len) with or without dexametasone (Dex) in subjects newly diagnosed multiple myeloma (NDMM)

Cancer type: Myeloma

Phase: I/II

Principal Investigator: Porkka Kimmo

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion